However, at present, there is still a lack of comprehensive evaluation of the association between 18F-FDG PET/CT and EGFR mutations in patients with NSCLC, e.g., using 18F-FDG PET/CT to predict EGFR mutation status and then monitor treatment response and evaluate the outcome, which needs to be carried out simultaneously in a large sample retrospective or prospective study. This evidence concerns the gene EGFR and non-small cell lung carcinoma.